-
公开(公告)号：US08404637B2
公开(公告)日：2013-03-26
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
2.发明申请公开(公告)号：US20110136737A1
公开(公告)日：2011-06-09
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/22 , C07K14/645 , C07K14/605 , A61K38/26 , A61P3/10 , A61P9/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20090036364A1
公开(公告)日：2009-02-05
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20080312157A1
公开(公告)日：2008-12-18
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
5.发明授权公开(公告)号：US08497240B2
公开(公告)日：2013-07-30
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08263545B2
公开(公告)日：2012-09-11
申请号：US11840921
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08076288B2
公开(公告)日：2011-12-13
申请号：US11206903
申请日：2005-08-17
申请人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
发明人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US08697647B2
公开(公告)日：2014-04-15
申请号：US13323608
申请日：2011-12-12
申请人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
发明人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20120253023A1
公开(公告)日：2012-10-04
申请号：US13323608
申请日：2011-12-12
申请人： Odile Esther LEVY , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
发明人： Odile Esther LEVY , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack
IPC分类号： C07K19/00
CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
公开(公告)号：US20090286723A1
公开(公告)日：2009-11-19
申请号：US12063420
申请日：2006-08-11
申请人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack , Behrouz Bruce Forood
发明人： Odile Esther Levy , Michael R. Hanley , Carolyn M. Jodka , Diana Y. Lewis , Christopher J. Soares , Soumitra S. Ghosh , Lawrence J. D'Souza , David G. Parkes , Christine M. Mack , Behrouz Bruce Forood
IPC分类号： A61K38/22 , C07K2/00 , C07K14/585 , C07K14/605 , C07K14/575 , A61P3/10 , A61P9/00
CPC分类号： C07K14/575 , A61K38/00 , C07K2319/00
摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关 条件。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.082 秒)
